RecruitingNCT06732349

Urinary Tubular Biomarkers for Chronic Kidney Disease

Sponsor

Erasmus Medical Center

Enrollment

556 participants

Start Date

Jan 1, 2025

Study Type

OBSERVATIONAL

Conditions

Chronic Kidney Disease Stage 3

Summary

Currently used tests for chronic kidney injury only assess the function of one part of the kidney: the filter called the glomerulus. The other part, called the tubule, is disregarded. Based on many previous studies, the investigators have good reason to assume that a better prediction of the course of chronic kidney disease by testing tubular function will be possible. This is important, for example, when patients need to be treated with kidney-protecting drugs.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is measuring specific proteins (biomarkers) in the urine of people with chronic kidney disease (CKD) to better understand how the kidney tubules (the filtering tubes inside the kidney) are being damaged. The goal is to find better ways to monitor CKD progression. **You may be eligible if...** - You have been diagnosed with Stage 3 chronic kidney disease (your kidney filtration rate is between 30 and 59 mL/min) **You may NOT be eligible if...** - You have active glomerulonephritis (kidney inflammation) currently being treated with immunosuppressive drugs - You have had a kidney transplant - You are currently receiving chemotherapy or immunotherapy for cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTUrinary tubular test panel

The urinary tubular test panel will be applied to urine samples that are collected as part of the routine outpatient follow-up. Its predictive power for CKD progression will be assessed. The results of the tubular test panel will not influence the treatment of the patients. They will remain under standard outpatient treatment throughout the study.